Incentives and disincentives to participation by clinicians in randomised controlled trials

J M Rendell1, R D Merritt, J R Geddes

  • 1University of Oxford, Psychiatry, Department of Psychiatry, Warneford Hospital, Oxford, UK, OX3 7JX. jennifer.rendell@psych.ox.ac.uk

Abstract

Insights

Clinician incentives and disincentives impact patient recruitment in randomized controlled trials (RCTs). Understanding these factors is crucial for improving trial participation and advancing healthcare research.

Area of Science:

  • Clinical Trials Methodology
  • Health Services Research
  • Evidence-Based Medicine

Background:

  • Clinicians and patients require reliable data from randomized controlled trials (RCTs) regarding treatment costs and benefits.
  • Recruitment challenges in RCTs often stem from clinicians not inviting eligible patients to participate.

Purpose of the Study:

  • To evaluate evidence on how disincentives and incentives influence clinicians' invitation of eligible patients to participate in healthcare intervention RCTs.
  • To assess evidence related to clinicians' stated willingness to invite patients to trials.

Main Methods:

  • Searched multiple databases including Cochrane Methodology Register, EMBASE, MEDLINE, CINAHL, PsycINFO, and AMED.
  • Included eleven observational studies exploring the effects of (dis)incentives on clinicians' views and recruitment activities.
  • Extracted data on (dis)incentives and tested associations with recruitment, noting limitations in quality assessment.

Main Results:

  • No RCTs of interventions were identified; eleven observational studies were included.
  • Clinicians acquainted with researchers were less likely to participate (OR 0.4).
  • Recruitment difficulties cited by clinicians included extra work (OR 92.94) and embarrassment (p < 0.0001), with concerns about the doctor-patient relationship acting as a deterrent (p = 0.007).

Conclusions:

  • The influence of various factors on clinician willingness to invite patients to RCTs varies.
  • Trial design and conduct aspects can significantly affect clinicians' willingness to recruit.
  • Further research is necessary to fully understand and address these recruitment barriers.

Related Concept Videos

Blinding01:11

Blinding

Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
Randomized Experiments01:13

Randomized Experiments

The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Blind Procedures02:07

Blind Procedures

Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which child was...